JPMorgan downgraded Xencor (XNCR) to Neutral from Overweight with a price target of $13, down from $18. The firm views the company’s 2026 as an “execution year.” Xencor’s pipeline will need time to develop, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XNCR:
- Xencor’s Lung Cancer Trial Halted: What the Vudalimab Update Means for XNCR Investors
- Xencor, Genentech to End Protein Therapeutics Collaboration
- Xencor reports receipt of notice of termination of license agreement from Roche
- Controversial Prasad leaving FDA, NYT reports
- Xencor: Buy Rating Reaffirmed on Pipeline Momentum Despite Ultomiris Royalty Headwind